Joëlle Guilhot - Concepedia

Author

Joëlle Guilhot

Also Known As

Didier M. Payen, Francoise Rigal-Huguet, Guilhot, Joelle, J GUILHOT, J Guilhot, J. Guilhot, Joelle Guilhot, Joëlle Guilhot, Joëlle Guilhot, Silver, Richard T.

221

Publications

10.8K

Citations

H-Index

Concepts

All Affiliations

Inserm Centre Hospitalier Universitaire de Poitiers Université de Poitiers Hôpital Saint-Louis Institut Bergonié

About

Joëlle Guilhot is an author at Inserm specializing in medicine, oncology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	32	4.4K
2	Health Sciences	11	12	2.6K
3	Public Health	3	3	320
4	Natural Sciences	2	2	120
5	Biomolecular Engineering	1	1	16

Joëlle Guilhot

Publications

9.5K

Citations

H-Index

Page 1

	Year	Citations
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial François‐Xavier Mahon, Delphine Réa, Joëlle Guilhot, The Lancet Oncology Hematological MalignancyOncologyChronic Myeloid LeukaemiaHematologyMyeloid Neoplasia	2010	1.5K
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial Johan Richter, Joëlle Guilhot, Franz Gruber, The Lancet Oncology Hematological MalignancyMedicineChronic Myeloid LeukaemiaMixed-phenotype Acute LeukemiaHematology	2018	587
Interferon Alfa-2b Combined with Cytarabine versus Interferon Alone in Chronic Myelogenous Leukemia François Guilhot, Claude Chastang, Mauricette Michallet, New England Journal of Medicine	1997	553
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score Joerg Hasford, Michele Baccarani, Verena Hoffmann, Blood	2011	492
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia Gabriel Étienne, Joëlle Guilhot, Delphine Réa, Journal of Clinical Oncology Hematological MalignancyStop ImatinibChronic Myeloid LeukemiaPurpose ImatinibMedicine	2016	484
Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease Philippe Rousselot, Aude Charbonnier, Pascale Cony‐Makhoul, Journal of Clinical Oncology	2013	405
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia Claude Preudhomme, Joëlle Guilhot, Franck E. Nicolini, New England Journal of Medicine	2010	382
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study Delphine Réa, Franck E. Nicolini, Michel Tulliez, Blood	2016	314
Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia Markus Pfirrmann, Michele Baccarani, Joëlle Guilhot, Leukemia Hematological MalignancyChronic Myeloid LeukemiaOncologyLongevityMixed-phenotype Acute Leukemia	2015	289
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries Verena Hoffmann, Michele Baccarani, Joerg Hasford, Leukemia Hematological MalignancyClinical PopulationClinical EpidemiologyHematologyEuropean Countries	2015	250

Page 1